The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | CLARITY for CLL: ibrutinib/venetoclax achieve MRD negativity in R/R setting
The CLARITY study (ISCRTN13751862), part of the Bloodwise Trials Acceleration Programme (TAP), was the first clinical trial to investigate the combination of venetoclax and ibrutinib for relapsed/refractory chronic lymphocytic leukemia (CLL), with the aim of eradicating detectable disease and stopping treatment. Here,Talha Munir, MBBS, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, updates us on the results of the study; highlighting the tolerability, and high response and MRD eradication rates, in some cases leading to the cessation of therapy. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
